stars 1 stars 2 stars 3

Founded in 2010, Amoéba is an innovative industrial greentech specialised in the treatment of microbiological risk of natural resources. Our biosolutions are based on a unique micro-organism, the amoeba Willaertia magna C2c Maky. Thanks to our scientific, industrial and commercial know-how, we are able to provide biological alternatives for different applications and industries. 𝙊𝙐𝙍 𝙎𝙊𝙇𝙐𝙏𝙄𝙊𝙉𝙎 💄 Cosmetics : Our latest innovation offers anti-aging and UV protection properties. In October 2023, in vitro studies showed that this lysate stimulates cellular functions, activates wound healing genes, promotes hyaluronic acid synthesis, and enhances anti-infective immunity. These benefits were confirmed in a spring 2024 clinical study, with statistically significant results. Amoéba has successfully registered this ingredient on the INCI list, facilitating its commercialization and establishing it as a key player in innovative skincare solutions. 🌱 Biocontrol "AXPERA": Our second technology enables plant protection in agriculture and is based on the antifungal properties of the amoeba in its lysed (non-living) form. In 2022, the US Environmental Protection Agency (US EPA) has granted approval for the use of our solution in agriculture in the USA. In the same year, Austria issued a positive recommendation for the approval of our active substance in Europe. With this innovation, Amoéba contributes to an efficient, secure and more virtuous biological agriculture. 💧 Biocide "BIOMEBA": This historical application, initiated at the foundation of the company, enables the treatment of water in cooling towers and uses the amoeba Willaertia magna C2c Maky in its living form. In 2022, the US EPA has approved the use of our active substance in closed cooling systems in the USA, making our solution the first biological biocide approved for global industrial water treatment. Youtube 👉 @AmoebaNature X 👉 @AmoebaNature

Website https://amoeba-nature.com
Revenue $8.2 million
Employees 37 (10 on RocketReach)
Founded 2010
Industry Biotechnology Research
Competitors Thermo Fisher Scientific, Veolia, Ecolab, Merck Group, Xylem, Danaher Corporation, SUEZ, PerkinElmer, Inc., Bio-Rad Laboratories, Geno +30 more (view full list)

Amoéba Questions

The Amoéba annual revenue was $8.2 million in 2026.

Jean-François Doucet is the Directeur général of Amoéba.

10 people are employed at Amoéba.

Top Amoéba Employees

View Similar People
Learn More
How It Works
get free account
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups.
search page
Search the #1 Contact Database
Get contact details of over 700M profiles across 60M companies – all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
get contact page
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users